The Column Group — Full Portfolio

ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.

BiotechHealthtechSouth San Francisco, US

RHRichard Heyman(Chairman, Founder, Scientific Advisory Board)inCSCharles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)DPDominic Piscitelli(Chief Financial Officer)inPMPratik Multani(Chief Medical Officer)inJCJacob Chacko(President, Chief Executive Officer and Board Member)in

Co-investorsECEcoR1 CapitalNENew Enterprise Associates (NEA)NENextech InvestTATaiho Ventures, LLCVIViking GlobalOROrbiMed

Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.

BiotechHealthtechMedical DevicesRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)

Co-investorsBABain Capital Life SciencesFOForesite CapitalGEGen CapitalGVGV (Google Ventures)ILIllinois VenturesNENextech Invest+2 more

Tenaya Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease.

BiotechHealthtechSouth San Francisco, US

DSDeepak Srivastava, M.D.(Scientific Founder)inEOEric Olson, Ph.D.(Scientific Founder)BRBruce R. Conklin, M.D.(Scientific Founder)inSDSheng Ding, Ph.D.(Scientific Founder)SHSaptarsi Haldar, M.D.(Scientific Founder)inEric Hyllengren(Chief Financial Officer)in

Co-investorsGVGV (Google Ventures)RARA CapitalVEvenBio Partners

Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.

AI & Machine LearningBiotechWatertown, US

Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRGRobert Gagnon(Executive Officer)HWHeather Wasserman(Executive Officer)inMPMatthew Patterson(Director)inSBScott Biller(Director)in

Board seatJGJeff Goater· per SEC Form D

Co-investorsATAtlas VentureFOForesite CapitalARARCH Venture PartnersALAlexandriaDEDecheng Capital

Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology.

BiotechHealthtechMedical Devices

Bryan E. Stuart(Chief Executive Officer)inMDMarion Dorsch(President and Chief Scientific Officer)inJared Rutter(Founder)John Tallarico(Founder)Ralph DeBerardinis(Founder)

Co-investorsLULux CapitalRARA CapitalNENextech Invest

InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers.

BiotechDeep TechMedical DevicesSeattle, US

KCK. Chris Garcia(Scientific Founder)PRPrakash Raman(CEO)inAJAmanda J. Redig(Chief Medical Officer)inSLScott Lesley(President & CSO)inPHPamela Holland(SVP of Biology)inSJSally Johnson(Chief People Officer)in

Co-investorsMRMRL Ventures FundVIVida Ventures

Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.

BiotechHealthtechCambridge, US

AFAndrew Fraley(Judo Bio Co-Founder)inASAlfica SehgalinOCOMMER CHOHAN(Executive Officer)inJAMES JEFFREY GOATER(Executive Officer, Director)SRSimon Read(Executive Chair and Acting CEO)inWHWilliam Ho

Co-investorsATAtlas VentureDIDigitalis VenturesDRDroia VenturesYKYK Bioventures

Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.

BiotechDeep TechDigital HealthHealthtechMedical Devices

Co-investorsSASamsara BioCapitalSASanofi Ventures

Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.

BiotechHealthtech

K. Christopher Garcia(Founder)SMSusan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)

Co-investorsSASamsara BioCapitalBABain Capital Life SciencesCACanaan PartnersRARA CapitalTCTCG CrossoverDEDeerfield Management Company+2 more

A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.

BiotechDeep TechDigital HealthHealthtechMedical DevicesAgoura Hills, US

CAC. Alexander Kamb(Director)inJRJim Robinson(CEO)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)

BoardSASrini Akkaraju(Director)in

Board seatDVDavid V. Goeddel· per SEC Form D

Co-investorsCACasdin CapitalMAMana VenturesNENextech InvestVIVida VenturesSASamsara BioCapital

Carmot is a clinical-stage biotechnology company developing novel treatments for obesity and type 2 diabetes through biased receptor agonist compounds.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMedical DevicesBerkeley, US

Daniel A. Erlanson(Executive Officer, Director)Stig K. Hansen(Executive Officer, Director)HTHeather Turnerin

BoardAetna Wun Trombley(Director)

Board seatPeter SvennilsonTim KutzkeyTKTim KutzkeyLLLarry Lasky· per SEC Form D

Co-investorsFRFrazier Life SciencesHOHorizons VenturesRARA CapitalTCTCG Crossover

Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

MPMatthew P. Jacobson(Co-founder)Scott R. Lokey(Director)DJDavid J. Earp(President & CEO)inPaul Park(Executive Officer)

BoardTSThilo Schroeder(Director)inWHWalter H. Moos(Director)

Board seatJJJohn JoseyJEJames EvangelistaPSPeter Svennilson· per SEC Form D

Co-investorsBEBerkeley CatalystHEHemisphere Ventures LLCJUJude GomilaLILifeforce CapitalMIMission Bay CapitalMIMission Biocapital+4 more

Developing therapeutics targeting epigenetic regulators to modulate gene expression; acquired by MorphoSys in June 2021 for $1.7B.

BiotechHealthtechCambridge, US

Michael R. Cooper(Executive Officer)inJEJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)inTom Maniatis(Director)

Board seatPSPeter SvennilsonDVDavid V. Goeddel· per SEC Form D

Co-investorsAVAvoro Capital AdvisorsBABain Capital Life SciencesVEVenrockTHThird Rock Ventures

Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.

BiotechHealthtechSouth San Francisco, US

Jeremy Bender(Executive Officer, Director)

BoardMGMichael Gladstone(Director)inDDDerek DiRocco(Director)inJPJulie Papanek Grant(Director)inDaniel Becker(Director)

Board seatJJJohn Josey· per SEC Form D · $130M raise · filed Feb 2021

Co-investorsACAccess BiotechnologyATAtlas VentureCACanaan PartnersVIViking GlobalACAccess IndustriesRARA Capital

Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications.

BiotechDeep TechHealthtechMenlo Park, US

CJColin James Bell Harvey(Director)BTBrian T. Naughton(Director)inMHMaureen Hillenmeyer(CEO & Co-Founder)in

BoardAlex Kolich(Director)

Board seatDVDavid V. Goeddel· per SEC Form D

Co-investorsATATEL VenturesB3B3 HoldingNENextech InvestSOSoftBank Vision Fund8V8VCCACasdin Capital+1 more

Kallyope is a biotechnology company founded by neuroscientists that discovers and develops novel therapeutics targeting neural networks, with a lead candidate in pivotal studies for acute migraine treatment and metabolism programs approaching clinical studies.

BiotechHealthtechNew York City, US

TMTom Maniatis(Founder)Nancy Thornberry(Executive Officer, Director)inKenneth Clark(Executive Officer)Charles Zuker(Founder)Richard Axel(Founder)

BoardTMTerry McGuire(Director)in

Board seatTKTim Kutzkey· per SEC Form D

Co-investorsDNDns CapitalILIllumina VenturesLULux CapitalPOPolaris PartnersTWTwo Sigma Ventures

Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.

BiotechDeep TechHealthtechSouth San Francisco, US

CNCory Nicholas(Executive Officer, Director, Promoter)inJSJames Stutz(Chief Financial Officer and Chief Business Officer)inCPCatherine Priest(Chief Development Officer)inGBGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)

Board seatPeter SvennilsonTim KutzkeyDVDavid V. Goeddel· per SEC Form D

Co-investorsBEBerkeley FrontierIAIaso VenturesVIViking GlobalYSYsios CapitalALAlexandriaFIFidelity Investments+8 more

NGM Bio is a biopharmaceutical company developing NGM120, a GDF15/GFRAL antagonist antibody, to treat conditions rooted in overactivation of the GDF15 pathway.

BiotechHealthtechSouth San Francisco, US

Diana Peng Bockus(Executive Officer, Director)

BoardRoger M. Perlmutter(Director)

Board seatPeter SvennilsonTim Kutzkey· per SEC Form D

Co-investorsRHRho Ventures

Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US

ATArthur T. Sands(Executive Officer, Director)inGMGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)

BoardDGDavid Goeddel(Director)inMark Goldsmith(Director)

Board seatDVDavid V. Goeddel· per SEC Form D

Co-investorsBABain Capital Life SciencesECEcoR1 CapitalFOForesite CapitalGEGeneral AtlanticSOSofinnova VenturesWEWellington Management+1 more

BiotechLexington, US

VMVictoria M. Richon(Executive Officer, Director)in

BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)

Board seatJGJeff Goater· per SEC Form D

Co-investorsAVAvego BioScience CapitalOUOUP (Osage University Partners)PEPeregrine VenturesABAbbVieDEDeerfield Management CompanyJJJJDC+3 more

Surrozen develops multifunctional biologic therapies that selectively activate Wnt signaling to address ophthalmic diseases with unmet medical needs.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Anna Berkenblit(Director)Harold Varmus(Director)

BoardDGDavid Goeddel(Director)inCPCraig Parker(Executive Officer, Director)

Board seatDVDavid V. GoeddelTKTim Kutzkey· per SEC Form D

Co-investors5A5AM VenturesACAccess BiotechnologyHOHorizons Ventures

Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.

BiotechHealthtechLongevity

Co-investorsATAtlas VentureDRDroia VenturesECEcoR1 CapitalGVGV (Google Ventures)ABAbbVieJJJJDC+3 more

Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small molecule and monoclonal antibody combination therapies for people with cancer.

BiotechHealthtech

Juan Jaen(Co-founder & President)inTerry Rosen(Co-founder & Chief Executive Officer)inBob Goeltz(Chief Financial Officer)inRMRichard Markus(Chief Medical Officer)inCTCarolyn Tang(General Counsel)inYvonne Gehring(SVP, Human Resources)in

Co-investorsAIAisling CapitalDEDecheng CapitalDRDroia VenturesECEcoR1 CapitalFOForesite CapitalGVGV (Google Ventures)+4 more

Tau provides formal verification of compiled binaries by generating mathematical proofs of correctness or identifying bugs, addressing risks from AI-assisted code generation and complex software systems.

AI & Machine LearningCybersecurityDeveloper ToolsEnterprise SoftwareSan Francisco, US

PNPedro Nobre(CEO)inLJLuke Johnston(CTO)in

Co-investorsY Y CombinatorBLBlast.ClubFOFounders FactoryLULux CapitalUNUnpopular Ventures

Cajal Therapeutics develops novel therapies through translating scientific advances into treatments for patients.

AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesSeattle, US

Andrew Dervan(Co-Founder and Co-Chief Executive Officer)inIPIan Peikon(Co-Founder and Co-Chief Executive Officer)inRHRob Hershberg(Co-Founder and Executive Chairman)in

Co-investorsLULux CapitalDODolby Family Ventures

Calithera Biosciences was a clinical-stage biopharmaceutical company developing small-molecule oncology drugs targeting tumor metabolism, including the glutaminase inhibitor telaglenastat.

BiotechSouth San Francisco, US

Susan M. Molineaux(Executive Officer, Director)inWWWilliam Waddill(Executive Officer)in

BoardJean M. George(Director)DPDeepa Pakianathan(Director)inRalph E. Christoffersen(Director)Jonathan Drachman(Director)

Co-investorsLOLongwood FundVEVenture Capital Investment Management

Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications.

BiotechDeep TechHealthtechBoston, US

ABAndrea Ballabio(Founder)BLBeth Levine(Founder)Herbert Virgin(Founder)JHJames Hurley(Founder)in

Co-investorsASAstellas Venture Management LLCTHThird Rock VenturesEIEisai Innovation, Inc.ONOno Venture Investment, Inc.

Pioneering a drug discovery method based on tracking the movement of individual proteins in living cells.

Eric Betzig(Founder)Luke Lavis(Founder)Robert Tjian(Founder)Xavier Darzacq(Founder)

Co-investorsECEcoR1 CapitalGEGeneral CatalystHOHorizons VenturesLULux CapitalTCTCG CrossoverWPWPSS Investments+1 more

Company developing molecules targeting a novel class of receptors for neuro-immuno-inflammatory diseases; acquired by Incyte in May 2024.

BiotechSan Diego, US

Alain Baron(Founder)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Founder)

BoardASAndrew Schwab(Director)in

Co-investors5A5AM VenturesAVAvego BioScience CapitalNENew Enterprise Associates (NEA)OUOUP (Osage University Partners)SASanofi VenturesABAbingworth+2 more

Creating cancer therapeutics through novel immunology insights; acquired by Bristol-Myers Squibb in April 2015 for $1.3B.

BiotechSan Carlos, US

Juan Carlos Jaen(Executive Officer, Director)inTerry Rosen(Executive Officer, Director)inLBLuis Bayol(Executive Officer)in

BoardBSBeth Seidenberg(Director)inDave Goeddel(Director)William Rieflin(Director)

Co-investorsKLKleiner Perkins

Bob Swanson(Founder)Herb Boyer(Founder)Herbert Boyer(Founder)Robert Swanson(Founder)

Co-investorsKLKleiner PerkinsMAMayfield Fund

Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.

BiotechHealthtechMedical DevicesNew York, US

Co-investorsBRBrandon CapitalKLKleiner PerkinsNENew Enterprise Associates (NEA)NENextech InvestPRProspect Venture PartnersRHRho Capital Partners+3 more

Nexoplex Bio develops immunotherapies designed to target tumors through recognition of HLA-peptide complexes using multi-specific antibodies, aimed at cancers including certain lung, gastric, esophageal, head and neck, and cervical cancers.

BiotechHealthtechSan Carlos, US

AAAndrew Allen(Executive Officer, Director)inVassiliki Economides(Executive Officer)MHMatthew Hawryluk(Executive Officer)inWayne(CEO)Rachel(VP of Operations)Shefali Agarwal(Director)

Co-investorsFRFrazier Life SciencesGVGV (Google Ventures)SOSofinnova VenturesREREDMILEVEVersant Ventures

Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.

BiotechDeep TechHealthtechSan Carlos, US

Wayne(CEO)Rachel(VP of Operations)

Co-investorsBABay City CapitalGVGV (Google Ventures)LALAVLILilly Asia VenturesALAlexandriaFRFrazier Healthcare Partners+1 more

Immunotherapy oncology company engineering technologies to activate the immune system; acquired by Merck in February 2019 for $0.3B.

BiotechHealthtechMedical DevicesSeattle, US

DBDavid Baltimore(Director)Carlos V. Paya(Executive Officer, Director)Stephen R. Brady(Executive Officer)inJHJan Henrik ter Meulen(Executive Officer)Paul Rickey(Executive Officer)inWayne Gombotz(Executive Officer)in

Co-investorsAIAisling CapitalATAtlas VentureHMHM Venture PartnersOUOUP (Osage University Partners)SASanderling VenturesSASanofi Ventures+4 more

Kenai Therapeutics develops iPSC-derived cell therapies and gene-modified medicines for neurodegenerative diseases, particularly Parkinson's disease, leveraging induced pluripotent stem cell technology to replace damaged neurons and restore neural function.

BiotechDeep TechHealthtechMedical Devices

HFHoward Federoff(Scientific Co-Founder, Chief Medical Officer and Executive Vice President of Corporate Medicine and Science)in

Co-investorsCUCure Ventures

Kimia is a therapeutics company developing new drugs through its ATLAS platform, working with partners in the pharmaceutical and biotechnology industries.

AI & Machine LearningBiotechDeep Tech

SHStig Hansen(Founder)in

Co-investorsAIAirTree VenturesHOHorizons VenturesBLBlackbird VenturesDIDIMENSIONDIDimension CapitalSKSkip Capital

Lyterian Therapeutics develops pharmaceutical treatments by leveraging protein homeostatic mechanisms to target genetically-validated disease drivers.

BiotechDeep TechHealthtechSouth San Francisco, US

NILO develops technology to upcycle hard-to-recycle plastic waste, primarily polyethylene (PE) and polypropylene (PP), into materials for use in circular systems and safer products.

Circular EconomyCleantechNew Materials

Co-investorsARArc AngelsICIcehouse VenturesPAPacific Channel

Nilo Saúde provides AI agents and automation solutions designed for healthcare institutions to improve operational efficiency and financial outcomes.

AI & Machine LearningDigital HealthHealthtechSão Paulo, BR

Isadora Kimura(Founder)Rodrigo Grossi(Founder)Victor Marcondes(Founder)

Co-investorsCICitrino VenturesIKIKJ CapitalMAMAYA Capital VenturesTATau VenturesVOVox CapitalTHThe Fund

Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.

BiotechDeep TechHealthtechNew York, US

JGJeff Goater(Executive Officer, Director)inKim Seth(CEO)in

BoardTKTim Kutzkey(Executive Officer, Director, Promoter)in

Co-investorsDCDCVC (Data Collective)ALAlexandriaDCDCVC BioLULux Capital

Novartis is a pharmaceutical company that develops and markets prescription medicines for patients across therapeutic areas including multiple sclerosis, breast cancer, and inflammatory conditions.

BiotechHealthtechBasel, CH

Co-investorsCLClal Biotechnology IndustriesEXExSight VenturesLOLongitude CapitalTATachyon Ventures

Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.

BiotechDigital HealthMedical Devices

Co-investorsCUCurative VenturesFOForesite CapitalNENextech InvestRIRidgeback CapitalVIVida Ventures

The Faculty of Pharmacy and Biochemistry offers pharmacy and biochemistry degree programs, including a Pharmacy programme in English aligned with EU Directive 2005/36/EC for EU/EEA registration.

EdTech

Co-investorsVEVesna AdvisorsNENextech InvestRARA Capital

Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.

AI & Machine LearningBiotechDeep TechSan Diego, US

Michael Martin, Ph.D.(Chief Executive Officer, President)JFJorge F. DiMartinoinMMMichael Martin(President, Chief Executive Officer)inSMStephen Mullennix(Executive Officer)inSerge Messerlian, M.Sc., M.B.A.(Chief Executive Officer)

BoardSMSerge Messerlian(Director)in

Co-investorsAMaMoonCRCRV (Charles River Ventures)DCDCVC (Data Collective)M M VenturesNENeotribe VenturesPIPivotal Life Sciences+3 more

RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases.

BiotechHealthtech

Co-investorsFOForesite CapitalFRFrazier Life SciencesGVGV (Google Ventures)KLKleiner PerkinsMEMedicxiSOSolasta Ventures+1 more

Genentech is a biotechnology company that develops and manufactures breakthrough medicines in the United States, backed by a $50 billion commitment to U.S. manufacturing and scientific innovation.

AI & Machine LearningBiotechDigital HealthSouth San Francisco, US

Co-investorsAIAisling CapitalKLKleiner PerkinsNENew Enterprise Associates (NEA)

Monimoit develops cancer therapeutics by combining chemical proteomics, covalent-based molecular technologies, and patient-derived translational insights to target difficult-to-drug cancer-promoting proteins and overcome resistance to existing treatments.

BiotechDeep Tech

SyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists.

AI & Machine LearningBiotechDeep Tech

MSMaria Soloveychik(PhD)in

Co-investorsNONorth South VenturesOMOMX VenturesSOSOSV8V8VC

Tortugas Neuro is a neuroscience drug development company focused on the neurology and neuropsychiatry space, working to advance clinical-stage therapies for brain health.

BiotechHealthtech

Co-investorsANAN Venture PartnersCUCure Ventures

Topo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases.

BiotechHealthtechCambridge, US

HTHui Tian(Executive Officer, Director)inMadgalene Moran(Executive Officer, Director)MMMagdalene Moran(Chief Executive Officer)

BoardKKKarin Kleinhans(Director)Bruce Bean(Director)James Jeffrey Goater, Jr.(Director)

Co-investorsMRMRL Ventures FundSRSR One Capital Management

Tr1X is a biopharmaceutical company developing cell and gene therapies to cure autoimmune and inflammatory diseases with high unmet medical need.

BiotechDeep TechHealthtechMedical Devices

David(Co-Founder)MGMaria Grazia Roncarolo(Co-Founder, President and Head of R&D)

Co-investorsNENeva Sgr.